Introduction Lifelong anticoagulation is the cornerstone of the chronic thromboembolic
pulmonary hypertension (CTEPH) treatment regardless of the additional pulmonary …

Venous thromboembolism (VTE) is the third most common cardiovascular disease. For most
patients, the standard of treatment has long consisted on low-molecular-weight heparin …

Purpose Data describing treatment patterns of patients with venous thromboembolism (VTE)
patients in Scandinavia are scarce. This study sought to address this scarcity by describing …

Background: Direct oral anticoagulants (DOACs) have been used in acute pulmonary
thromboembolism as an alternative to warfarin due to drug interactions, narrow therapeutic …

Introduction: Pulmonary embolism (PE) exerts a significant morbidity and mortality burden
which is associated with major financial cost for healthcare systems and patients. Our study …

Abstract Purpose of Review We investigated the risk profiles of patients using direct oral
anticoagulants (DOAC) or vitamin K antagonists (VKA) in European cohort studies to …

Venous thromboembolism (VTE) may affects all parts of the venous circulation, but
frequently manifests as deep vein thrombosis or pulmonary embolism. Annually, around 10 …

Background In routine clinical practice, in most countries, patients with pulmonary embolism
(PE) are hospitalized for clinical surveillance and to start anticoagulant treatment. Clinical …

Представленный обзор посвящен современным представлениям об особенностях
антикоагулянтной и тромболитической терапии венозной тромбоэмболии и, в большей …

The presented review concerns contemporary views on specific aspects of anticoagulant
and thrombolytic treatment of venous thromboembolism and mostly of acute pulmonary …